Core Viewpoint - The National Medical Products Administration has approved the innovative drug Anlotinib (also known as Migalizumab) for the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adults, which is expected to benefit more patients in China and improve their quality of life [1][2]. Group 1: Drug Approval and Mechanism - Anlotinib is a monoclonal antibody drug developed using biotechnology, specifically designed to block key inflammatory cytokines (IL-23p19 subunit) in the gut, thereby regulating excessive immune responses [1]. - The drug has already been approved in multiple countries and regions, including the US, Europe, and Japan, indicating its international recognition and potential effectiveness [1]. Group 2: Disease Impact and Patient Demographics - Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic and recurrent condition that has seen an increase in prevalence in China due to lifestyle changes, with Crohn's disease affecting approximately 3-4 cases per 100,000 people and ulcerative colitis affecting 17-18 cases per 100,000 people [1]. - The disease predominantly affects young adults, leading to symptoms such as abdominal pain, diarrhea, and weight loss, which significantly impact patients' quality of life and can result in increased healthcare costs, approximately three times higher than that of the general population [2]. Group 3: Clinical Efficacy - Clinical studies indicate that about one-third of patients treated with Anlotinib can observe early improvements in intestinal inflammation within three months, and nearly half can achieve clinical remission after one year of treatment, marking a promising new option for patients who have not responded well to traditional medications or other biologics [2].

Core Insights - The article discusses the case of a woman diagnosed with severe ulcerative colitis, highlighting the chronic and recurrent nature of the disease, which is a type of inflammatory bowel disease (IBD) [1][2] - It emphasizes the importance of dietary management for patients with ulcerative colitis to control symptoms and prevent relapses [2] Group 1: Disease Overview - Ulcerative colitis is characterized by non-specific inflammation of the intestinal mucosa, typically starting from the rectum and potentially affecting the entire colon [1] - The peak age of onset in China is between 20 to 49 years, with the exact causes still unclear, though environmental, genetic, gut microbiota, and immune factors are believed to contribute [1] Group 2: Symptoms and Diagnosis - Typical symptoms of ulcerative colitis include recurrent abdominal pain, diarrhea, and mucus or bloody stools, with severe cases presenting fever, fatigue, and anemia [2] - Some patients may also experience extraintestinal manifestations such as joint pain and pyoderma gangrenosum [2] Group 3: Dietary Management - Dietary management is crucial for controlling the condition, with key principles being a gentle, easily digestible, and nutritionally balanced diet [2] - Foods to avoid include: - Irritating spices: chili, pepper, garlic, mustard [4] - Hard-to-digest foods: fried foods, barbecued items, hard legumes, and high-fiber vegetables [5] - Cold foods: ice cream, chilled drinks, raw fish, and cold dishes [6] - Gas-producing foods: legumes, onions, cabbage, and carbonated drinks, which may exacerbate bloating [7] - Alcohol and tobacco should be strictly avoided as they can irritate the intestinal mucosa and increase the risk of disease relapse [7]

Core Viewpoint - The research published in Science reveals a novel Aeromonas variant (MTB) that produces aerolysin, which damages intestinal macrophage barriers and drives the occurrence of ulcerative colitis (UC), providing new insights into the etiology, diagnosis, and treatment strategies for UC [4][9]. Group 1: Mechanism of Ulcerative Colitis - Ulcerative colitis (UC) is a multifactorial disease involving immune dysregulation, genetic susceptibility, abnormal inflammatory responses to gut microbiota, and environmental factors [3]. - The study identifies that the function of resident macrophages in the intestines of UC patients is impaired, leading to compromised epithelial integrity [6]. - The depletion of macrophages occurs prior to the onset of visible inflammation, suggesting a critical role of these cells in maintaining gut health [6]. Group 2: Discovery of Aeromonas sp. MTB - The research team discovered a macrophage-toxic variant of Aeromonas, named Aeromonas sp. MTB, which expresses the virulence factor aerolysin [7]. - Macrophages exhibit higher sensitivity to cell death induced by aerolysin compared to epithelial cells, leading to barrier dysfunction without directly damaging epithelial cells [7]. - The presence of MTB in UC patients' fecal samples was significantly higher compared to healthy controls, indicating its potential role in UC pathogenesis [9]. Group 3: Experimental Findings - In mouse models, the presence of MTB exacerbates colitis symptoms, resembling UC, particularly in conditions of chemical or genetic macrophage depletion [8]. - Treatment with polyclonal anti-aerolysin antibodies can prevent MTB-induced colitis, while monoclonal antibodies can improve established colitis [8]. - The study emphasizes the microbial mechanisms promoting UC and suggests targeting bacterial virulence factors as a novel therapeutic strategy [9].

Core Insights - The article highlights the rising prevalence of Inflammatory Bowel Disease (IBD) in China, with current incidence rates ranging from 1.96 to 3.14 per 100,000 people, particularly affecting young adults [1] Misconceptions about IBD - Misconception 1: IBD is merely diarrhea; it includes Ulcerative Colitis (UC) and Crohn's Disease (CD), which are chronic inflammatory conditions affecting the gastrointestinal tract, with symptoms like abdominal pain, weight loss, and severe complications [2] - Misconception 2: IBD is a diet-related disease; while diet can influence symptoms, IBD is linked to genetic susceptibility and immune dysfunction, not directly caused by food [3] - Misconception 3: IBD patients cannot marry or have children; while there is a hereditary risk, many IBD patients successfully have healthy pregnancies with proper medical management [4] - Misconception 4: IBD requires long-term maintenance therapy; abrupt discontinuation of medication can lead to rebound inflammation, with studies showing a 60% five-year remission rate with regular treatment [5] - Misconception 5: IBD inevitably leads to cancer; while uncontrolled inflammation increases cancer risk, regular monitoring and treatment can mitigate this risk [6] - Misconception 6: Surgery can cure IBD; surgery is only for complications and does not eliminate the disease, with a high recurrence rate post-surgery [7] - Misconception 7: IBD patients should avoid exercise; moderate exercise can improve gut motility and quality of life, with recommendations for low-intensity activities [8] - Misconception 8: IBD can only be managed with Western medicine; a combination of Western and alternative therapies can provide a personalized treatment approach [9] - Misconception 9: IBD is an incurable disease; it is now considered a manageable chronic condition, with over 80% clinical remission rates achievable through proper treatment [10] Research and Development - Global research on IBD is advancing rapidly, with innovative treatments like fecal microbiota transplantation and CAR-T cell therapy entering clinical trials in China, potentially leading to breakthroughs in the next decade [11] - The focus is shifting towards precision diagnosis, individualized treatment, and accelerated drug development, aiming for a future where patients can coexist peacefully with IBD [12]